Swarm Oncology

Executive Summary

Swarm Oncology is a UK-based biotech company founded in 2018, pioneering personalized T cell therapies for cancer. Its platform uniquely combines in vivo priming with ex vivo optimization to generate highly targeted, durable, and cost-effective treatments. By leveraging each patient's tumor-specific biology, the company aims to drive cancers into long-term remission. Although still in preclinical stages, Swarm's approach addresses key limitations of current cell therapies, such as high cost and limited durability. The company operates in the rapidly evolving cell and gene therapy space, with potential to differentiate through its personalized in vivo/ex vivo hybrid strategy.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement50% success
• Q1 2027Initiation of IND-Enabling Studies60% success
• Q2 2027Publication of Preclinical Proof-of-Concept Data80% success